Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

“…The use of long-term hormone therapy in combination with conventional doses (65-70 Gy) of external beam radiation therapy has been shown to contribute to improved therapeutic outcomes in patients with localized prostate cancer, particularly those at high risk, whereas short-term neoadjuvant hormone therapy is believed to contribute to improved therapeutic outcomes in patients at moderate risk. [17][18][19][20][21][22][23][24] However, the evidence for these indications is based on radiation doses of 65-70 Gy, and the value of ADT in combination with !76 Gy radiation doses remains unclear. Opinions on this point are divided, as some studies have found no association between ADT and therapeutic outcomes of !76 Gy IMRT, whereas others have reported improved DMFS.…”

Survivorship and Improving Quality of Life in Men with Prostate Cancer

“…Despite its acknowledged anti-cancer benefits [27][28][29], androgen deprivation therapy (ADT) is associated with a range of adverse effects in survivors. These have been extensively covered in a recent review in European Urology.…”

Use of androgen deprivation therapy in prostate cancer: indications and prevalence

“…Three months of ADT had no effect on these parameters, although it did prolong time to PSA progression, time to local progression and event-free survival. 36 Two trials have compared an even longer duration of ADT with short duration of ADT in patients with locally advanced and generally high-risk disease. RTOG 9202 randomized patients to 4 months vs. 28 months of ADT, commencing 2 months prior to RT.…”